ライフサイエンスコーパス: influenza

1 g children aged 6 months to 17 years against influenza.

2 cal disease or other risk factors for severe influenza.

3 to hospital occurred with RSV compared with influenza.

4 8%) of 626 patients had laboratory-confirmed influenza.

5 tering oseltamivir alone in the treatment of influenza.

6 were hospitalized with laboratory-confirmed influenza.

7 or patients admitted to hospital with severe influenza.

8 IFITM3 has not been evaluated in pediatric influenza.

9 ute respiratory illness testing negative for influenza.

10 entative DNA and RNA viruses, namely, T4 and influenza.

11 with influenza-like illness were tested for influenza.

12 stay of the public health strategy to combat influenza.

13 Here, we show that both 2009 pandemic H1N1 influenza A (H1N1) virus and highly pathogenic avian inf

14 a A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus induce expression of tumor necr

15 Quantitative screening of influenza A (H7N9) virus without DNA amplification was p

16 Influenza A H3N2 variant [A(H3N2)v] viruses have caused

17 After influenza A infection of immunologically naive ferrets w

18 formulations including the hemagglutinins of influenza A subtypes H1N1 and H3N2 and B lineages Yamaga

19 respiratory epithelial cells in response to influenza A virus (IAV) infection, as well as the CHIP-s

20 e T cells in children to genetically diverse influenza A virus (IAV) strains to which the children ha

21 rcoma-associated herpesvirus (KSHV), against influenza A virus (IAV) were investigated in vitro and i

22 on the virion surface, is important in both influenza A virus assembly and entry.

23 The NS1 protein from all strains of influenza A virus binds TRIM25, although not all virus s

24 The data suggest that influenza A virus budding and genome incorporation can o

25 discuss the implications of reassortment for influenza A virus evolution, including its classically r

26 n.Broadly reactive antibodies that recognize influenza A virus HA can be protective, but the mechanis

27 Susceptibility to colitis and influenza A virus infection occurring upon commensal bac

28 ficantly affect adaptive immune responses to influenza A virus infection, with their effect on the ou

29 the microminipig as a novel animal model for influenza A virus infection.

30 S2 plays an important and unexpected role in influenza A virus infection.

31 ergetic barrier to pore expansion.IMPORTANCE Influenza A virus is an airborne pathogen causing season

32 sm underlying the genetic diversification of influenza A virus is reassortment of intact gene segment

33 The influenza A virus M1 and M2 proteins play important role

34 Influenza A virus mRNAs are transcribed by the viral RNA

35 The influenza A virus nucleoprotein (NP) is an essential mul

36 we identify several acetylation sites of the influenza A virus nucleoprotein (NP), including the lysi

37 nsider the constraints and drivers acting on influenza A virus reassortment, including the likelihood

38 virus, in 1958, 16 different novel, zoonotic influenza A virus subtype groups in 29 countries, Taiwan

39 n antiviral response, whereas infection with influenza A virus, herpes simplex virus 1, or cytomegalo

40 ng CD4 effector population, and they mediate influenza A virus-specific cytotoxic activity.

41 ng to the genetic and antigenic diversity of influenza A viruses (IAV) currently circulating in swine

42 Influenza A viruses (IAVs) cause seasonal epidemics and

43 Different influenza A viruses (IAVs) infect the same cell in a hos

44 The risk of emerging pandemic influenza A viruses (IAVs) that approach the devastating

45 These findings indicate that LP avian H7 influenza A viruses are able to infect and cause disease

46 to pigs resulted in substantial evolution of influenza A viruses infecting swine, contributing to the

47 The RNA genome of influenza A viruses is transcribed and replicated by the

48 can wild birds are an important reservoir of influenza A viruses, yet the potential of viruses in thi

49 virucidal for H1 hemagglutinin-bearing human influenza A viruses.

50 pacts multiple steps in viral replication of influenza A viruses.

51 f influenza B, and 6 cases of nonsubtypeable influenza A were detected.

52 vaccination for influenza A(H3N2) (p=0.004), influenza A(H1N1)pdm09 (p=0.01), and influenza B viruses

53 Analyses included 596 influenza A(H1N1)pdm09 and 305 B(Victoria) cases and 926

54 We included 3376 patients with influenza A(H1N1)pdm09, of whom 3085 (91.4%) had laborat

55 E with increasing time since vaccination for influenza A(H3N2) (p=0.004), influenza A(H1N1)pdm09 (p=0

56 Recent outbreaks of swine-origin influenza A(H3N2) variant (H3N2v) viruses have raised pu

57 es of representative highly pathogenic avian influenza A(H5) viruses from Vietnam were generated, com

58 ted 2 human cases of highly pathogenic avian influenza A(H5N1) virus infection, detected through popu

59 and reassortment of highly pathogenic avian influenza A(H5N1) viruses at the animal-human interface

60 Similar results were observed for influenza A/H1N1, influenza A/H3N2, and influenza B stra

61 A total of 181 cases of influenza A/H3N2, 47 cases of influenza B, and 6 cases o

62 results were observed for influenza A/H1N1, influenza A/H3N2, and influenza B strains.

63 In the tropics, influenza accounts for excess cardiovascular-related hos

64 substantial inaccuracies with GFT-predicted influenza activity compared with FluNet throughout Latin

65 significant association between PEx risk and influenza activity in children and adults and with RSV a

66 cients between observed and Google-predicted influenza activity trends were determined for each count

67 e effects of weather variability on seasonal influenza among different age groups remain unclear.

68 Latin America has a substantial burden of influenza and rising Internet access and could benefit f

69 Influenza and RSV were listed primary diagnoses in 56 (3

70 cipants who were aged at least 18 years with influenza and were at increased risk of complications we

71 models of Chlamydia, Haemophilus influenzae, influenza, and respiratory syncytial virus respiratory t

72 We calculated influenza-associated deaths for children younger than 5

73 estimates to represent the range of possible influenza-associated deaths in a season or year.

74 Elderly persons have the highest influenza-associated hospitalization and mortality rates

75 of non-respiratory causes of death to global influenza-associated mortality should be investigated.

76 INTERPRETATION: These global influenza-associated respiratory mortality estimates are

77 Among RIV4 recipients, the RT-PCR-confirmed influenza attack rate was 2.2% (96 cases among 4303 part

78 us, predominantly for A(H1N1)pdm09 (11%) and influenza B (7%).

79 y titer geometric mean fold increase against influenza B and (2) lower seroconversion rates against i

80 distance from Mexico and the proportions of influenza B cases among the countries during the post-pa

81 ly, in the United States, the proportions of influenza B cases in the pre-pandemic period (2003-2008)

82 for influenza A/H1N1, influenza A/H3N2, and influenza B strains.

83 0.004), influenza A(H1N1)pdm09 (p=0.01), and influenza B viruses (p=0.04).

84 f 181 cases of influenza A/H3N2, 47 cases of influenza B, and 6 cases of nonsubtypeable influenza A w

85 sociations of IFITM3 SNP rs12252 with severe influenza, but evidence of association and the mechanism

86 ere similar across sites, with 61% of annual influenza cases occurring during the austral winter (May

87 y, while the average increase in the monthly influenza cases was 14.6% (95% CI, 9.0%-21.0%), 12.1% (9

88 showed that the expected decrease in monthly influenza cases was 19.3% (95% credible interval [CI], 1

89 After influenza challenge, antigen-specific cells underwent se

90 life-threatening disease in RSV-ADV and RSV-influenza coinfection warrants further study.

91 ed Disease Surveillance (PAEDS) network: the Influenza Complications Alert Network (FluCAN) study and

92 ined as subjects aged >9 years admitted with influenza confirmed by polymerase chain reaction.

93 (MRR) to account for differences in risk of influenza death across countries by comparing GHE respir

94 Previous estimates of 250 000-500 000 annual influenza deaths are outdated.

95 d with a reduced length of stay and improved influenza detection and antiviral use, and appeared to b

96 hortening length of hospital stay, improving influenza detection and treatment, and rationalising iso

97 Furthermore, most estimates of influenza disease burden worldwide rely on passive senti

98 sm(s) by which allergic asthma may alleviate influenza disease outcome, focused on the hypothesis tha

99 iors and six random sequence samples of H3N2 influenza during the 2014-15 flu season in the U.S.

100 Because viral pandemics, such as influenza, Ebola, and Zika, are becoming more common, an

101 Winter holidays delay seasonal influenza epidemic peaks and shift disease risk toward a

102 rnet access and could benefit from real-time influenza epidemic prediction web tools such as Google F

103 ated the binding site of these aniline-based influenza fusion inhibitors, which significantly overlap

104 ondence and some local discrepancies between influenza genetic and antigenic evolution.

105 ind that both the nature of selection on the influenza genome and the accessibility of specific mutat

106 B and (2) lower seroconversion rates against influenza H1N1 than noncolonized participants with AD.

107 s and could be used to block transmission of influenza H1N1pdm09 in ferrets, compared to an irrelevan

108 The emergence of highly pathogenic avian influenza H5N1 viruses has raised concerns about their p

109 efficacy of chimeric VLPs (cVLPs) containing influenza HA and GPI-anchored CCL28 as antigen and mucos

110 mini-proteins of 37-43 residues that target influenza haemagglutinin and botulinum neurotoxin B, alo

111 Influenza hemagglutinin is a surface glycoprotein relate

112 espectively, using the small nine amino acid influenza hemagglutinin tag.

113 the cognate antigens cytomegalovirus pp65 or influenza hemagglutinin were able to present the antigen

114 In the fully adjusted model, VE against influenza hospitalization was 58.0% (95% confidence inte

115 .4.4 CVVs.IMPORTANCE Highly pathogenic avian influenza (HPAI) A(H5) viruses have circulated continuou

116 The highly pathogenic avian influenza (HPAI) H5N1 viruses continue to circulate in n

117 tality annually, and highly pathogenic avian influenza (HPAI) viruses along with other emerging influ

118 tential to mutate to highly pathogenic avian influenza (HPAI) viruses, but such viruses' origins are

119 cohorts characterized by different levels of influenza illness severity.

120 n mothers and infants of year-round maternal influenza immunisation in Nepal, where influenza viruses

121 oundation for complete and long-lasting anti-influenza immunity.

122 ugh population-based active surveillance for influenza in Bangladesh, to assess transmission and cont

123 mited data on the burden of disease posed by influenza in low- and middle-income countries.

124 a new association of rs34481144 with severe influenza in three influenza-infected cohorts characteri

125 Histones released during influenza induced cytotoxicity and showed strong binding

126 of rs34481144 with severe influenza in three influenza-infected cohorts characterized by different le

127 expression was up-regulated in the brains of influenza-infected mice and was elevated in cerebrospina

128 produced DAT and rescued antibiotic-treated influenza-infected mice.

129 n a point of care clinic to rapidly diagnose influenza infection and also determine which of the appr

130 accination may be effective in both reducing influenza infection and asthma attacks.

131 riate logistic regression with PCR-confirmed influenza infection as the outcome and vaccination statu

132 ematical model representing the course of an influenza infection to explore the possibility of extrac

133 We employed a murine model of influenza infection to identify these mechanisms.

134 olar macrophages to limit lung damage during influenza infection.

135 For laboratory-confirmed influenza infections in infants aged 0-6 months, immunis

136 Secondary outcomes included the number of influenza infections, noninfluenza infections, parent-re

137 munocompromised patients with long-term H3N2 influenza infections.

138 ian-origin IAVs in mammals.IMPORTANCE Canine influenza is a respiratory disease of dogs caused by two

139 Influenza is a serious hazard to human health that cause

140 nal pain (one [7%]), fatigue (one [7%]), and influenza-like illness (one [7%]) in three patients trea

141 ngeal swabs were collected from persons with influenza-like illness and tested for influenza virus by

142 oint was RT-PCR-confirmed, protocol defined, influenza-like illness between 14 days or more after vac

143 Patients attended with influenza-like illness were tested for influenza.

144 Immunisation reduced maternal febrile influenza-like illness with an overall efficacy of 19% (

145 Introductions of low-pathogenic avian influenza (LPAI) viruses of subtypes H5 and H7 into poul

146 The influenza M2 protein not only forms a proton channel but

147 suggest that prior exposure to H1 or type B influenza may differentially affect cross-reactivity of

148 nostic tests are based upon detection of the influenza nucleoprotein, which are limited in that they

149 In retrospective forecasts of historical influenza outbreaks for 95 US cities from 2003 to 2014,

150 However, influenza outbreaks generally spread rapidly among swine

151 Our findings suggest that the 2009 influenza pandemic has an evident impact on the relative

152 ure influenza pandemics, as in the 2009 H1N1 influenza pandemic.

153 vere morbidity and mortality during the 2009 influenza pandemic.

154 We simulated influenza pandemics in Chicago using agent-based transmi

155 limited supplies are not unlikely in future influenza pandemics, as in the 2009 H1N1 influenza pande

156 ion of six different viruses from a standard influenza panel is reported.

157 r epithelium is therefore a pivotal event in influenza pathogenesis.

158 clinical relevance of this protease in human influenza pathogenesis.

159 the protective efficacy of the pandemic H1N1 influenza (pH1N1) vaccine was substantially increased by

160 a pandemic strain versus a previous seasonal influenza, plays a crucial role in the monitoring, contr

161 8 by intranasal administration and course of influenza pneumonia, inflammatory, and tissue responses

162 Appropriate antiviral treatment of influenza-positive patients was more common in the POCT

163 human postvaccination sera with only type B influenza preexposure consistently showed good correlati

164 derived from sera with neither H1 nor type B influenza preexposure.

165 receptor, the HIV-1 gp41 fusion protein, the influenza proton channel, and the MCU pore.

166 tions, broadly reactive and highly sensitive influenza rapid diagnostic tests (IRDTs) are required.

167 52 was not associated with susceptibility to influenza-related critical illness in children or with c

168 Together with influenza, the non-influenza RNA respiratory viruses (NIRVs), which include

169 In adults, surveillance tests positive for influenza (RR, 1.02; 95% CI, 1.01-1.02), but not RSV (RR

170 open-label study conducted in the 2012-2013 influenza season at 5 US clinical sites.

171 Influenza vaccination during 2013-14 influenza season attenuated adverse outcome among adults

172 Blood samples were collected before the influenza season or vaccination to assess antibody and T

173 IV4) during the A/H3N2-predominant 2014-2015 influenza season, when antigenic mismatch between circul

174 During the 2015-16 influenza season, when pandemic H1N1 was the predominant

175 or more after vaccination and the end of the influenza season.

176 d vaccine effectiveness during the 2016-2017 influenza season.

177 arly among tropical countries with irregular influenza seasonality.

178 data pooled from the 2011-12 through 2014-15 influenza seasons.

179 differences in their ability to re-stimulate influenza-specific CD4 T cells ex vivo.

180 ter influenza vaccination, the proportion of influenza-specific CD4(+) T cells coexpressing CD161 was

181 nsmission in ferrets, a unique finding among influenza-specific mAbs.

182 n mobility proxies to explore the drivers of influenza spread in the US during 2002-2010.

183 nic mismatch between circulating and vaccine influenza strains resulted in the reduced effectiveness

184 els of immunity against a wide divergence of influenza subtypes as compared to traditional vaccines.

185 from laboratory-challenged animals or during influenza surveillance at county fairs.

186 t can be easily integrated into contemporary influenza surveillance systems to provide reliable estim

187 We calculated the proportion of hospitalized influenza that is associated with IAND and IAE, and inci

188 Together with influenza, the non-influenza RNA respiratory viruses (NI

189 ymptomatic persons with laboratory-confirmed influenza, to identify secondary infections.

190 Additionally, MEDI8852 blocked influenza transmission in ferrets, a unique finding amon

191 ent impact on the relative burden of the two influenza types.

192 ith increasing time since vaccination across influenza types/subtypes.

193 sed antibody response compared with standard influenza vaccination consisting of a single dose.

194 potential for self-administration can expand influenza vaccination coverage in developing countries.

195 Influenza vaccination during 2013-14 influenza season at

196 udy has investigated the association between influenza vaccination during pregnancy and ASD.

197 niors (65+ years) after high-risk groups for influenza vaccination during times of limited vaccine su

198 ological evidence base for continuing annual influenza vaccination in adults.

199 R, a booster strategy 5 weeks after standard influenza vaccination is safe and effective and induces

200 For persons with asthma, influenza vaccination may be effective in both reducing

201 target groups, timing, and cost of national influenza vaccination programs.

202 These data demonstrate that influenza vaccination promotes the prevalence of relevan

203 Influenza vaccination was associated with a reduction in

204 trimester-specific analyses, first-trimester influenza vaccination was the only period associated wit

205 During the acute response to influenza vaccination, CD19(pos), CD19(low), and CD19(ne

206 Finally, after influenza vaccination, the proportion of influenza-speci

207 hanisms underlying differential responses to influenza vaccination.

208 d-dose, egg-grown, quadrivalent, inactivated influenza vaccine (IIV4) during the A/H3N2-predominant 2

209 unogenicity of an avian H5N2 live attenuated influenza vaccine (LAIV H5N2) in healthy Thai adults and

210 older adults of a quadrivalent, recombinant influenza vaccine (RIV4) with a standard-dose, egg-grown

211 rol group) or 2 doses (booster group) of the influenza vaccine 5 weeks apart.

212 veness (VE) estimates for 2015-2016 seasonal influenza vaccine are reported from Canada's Sentinel Pr

213 ehold cohort maintained in part for study of influenza vaccine effectiveness (VE).

214 t of this change as part of its estimates of influenza vaccine effectiveness in 2015-2016.

215 The Influenza Vaccine Effectiveness Network evaluated the ef

216 attended acute respiratory illness in the US Influenza Vaccine Effectiveness Network using data poole

217 Even so, effectiveness of influenza vaccine for older adults has been reported to

218 Seasonal influenza vaccine formulas change almost every year yet

219 Influenza vaccine is known to have suboptimal immunogeni

220 seasonally recommended trivalent inactivated influenza vaccine or saline placebo in blocks of eight,

221 We observed decreasing influenza vaccine protection with increasing time since

222 of the more immunogenic high-dose trivalent influenza vaccine with a standard-dose vaccine to identi

223 ontrolled trial [cRCT]) used live attenuated influenza vaccine, 11 (7 cRCTs) used inactivated influen

224 uenza vaccine, 11 (7 cRCTs) used inactivated influenza vaccine, and 5 (1 cRCT) compared both vaccine

225 nant BALB/c mice immunized with subunit H1N1 influenza vaccine, we demonstrate the advantage of skin

226 ise compromised Ab production to inactivated influenza vaccine.

227 To date, only inactivated influenza vaccines (IIVs) are available to prevent CIV i

228 We have developed pandemic live attenuated influenza vaccines (pLAIVs) against clade 1 H5N1 viruses

229 eraction, to support development of improved influenza vaccines and vaccination strategies.

230 Seasonal influenza vaccines are transitioning to quadrivalent for

231 he immune correlates of protection for avian influenza vaccines cannot be determined from clinical st

232 Immune responses to influenza vaccines decline with age, reducing clinical e

233 Head-to-head comparisons of conventional influenza vaccines with adenovirus (Ad) gene-based vacci

234 g sequential administration of then-standard influenza vaccines.

235 We examined the association between influenza VE and time since vaccination among patients >

236 Influenza viral infections often lead to increased morta

237 The mean levels of influenza viral RNA shedding in asymptomatic and paucisy

238 The presence of influenza viral shedding in patients with influenza who

239 howed that this peptide physically destroyed influenza virions.

240 Live attenuated influenza virus (LAIV) vaccines have been shown to provi

241 xtremely powerful multivalent binders of the Influenza virus and other viruses, comparably little is

242 s with influenza-like illness and tested for influenza virus by real-time reverse-transcription polym

243 consecutive seasons was 7.2% and 11.6%, and influenza virus caused 18.9% and 34.2% of ILI episodes.

244 Seasonal human influenza virus continues to cause morbidity and mortali

245 defined as molecular diagnostic evidence of influenza virus in pharyngeal specimens collected during

246 of the hospitalized infants were tested for influenza virus infection and 1 tested positive.

247 y to provide better protection from seasonal influenza virus infection and improve pandemic preparedn

248 s can mediate more potent protection against influenza virus infection in animal models.

249 Innate sensing of influenza virus infection induces activation of programm

250 ieve an optimal antiviral response following influenza virus infection or immunization.Broadly reacti

251 Studies in preclinical models of influenza virus infections have shown that antibodies al

252 the pathogenicity and low incidence of avian influenza virus infections in humans, the immune correla

253 and M2 proteins in virus assembly.IMPORTANCE Influenza virus particle assembly involves the careful c

254 ve AMPylation also abolished HSP70-dependent influenza virus replication.

255 on is crucial for SPL-mediated inhibition of influenza virus replication.

256 ial for the replication and transcription of influenza virus RNA.

257 sequenced and analyzed 441 wild-bird origin influenza virus strains isolated from wild birds inhabit

258 RBS naturally varies across avian and human influenza virus subtypes and is also evolvable.

259 We used influenza virus to test whether the technology has appli

260 viruses, which offer discrimination between influenza virus types and subtypes.

261 A, including PIV5-NA, could improve seasonal influenza virus vaccine efficacy and provide protection

262 ding long-term cross-protection against H3N2 influenza virus when compared to other vaccination group

263 pic studies, the membrane-ordering effect of influenza virus, HIV, and Dengue virus FPs has been cons

264 t evidence of human infection with an animal influenza virus, in 1958, 16 different novel, zoonotic i

265 to identify the universal biomarker for the influenza virus, M1 protein.

266 participants, 1309 (19%) tested positive for influenza virus, predominantly for A(H1N1)pdm09 (11%) an

267 uss a range of pathogenic viruses, including influenza virus, respiratory syncytial virus, human immu

268 FP7 protected mice from influenza virus-induced lethality and reduced both proin

269 allergen-sensitized and challenged mice into influenza virus-infected mice resulted in reduced morbid

270 promote antiviral host defenses against the influenza virus.

271 gainst a lethal challenge dose of homologous influenza virus.

272 tection against respiratory reinfection with influenza virus.

273 of K186 and E186 among H3N8 CIVs and equine influenza viruses (EIVs), the ancestors of H3N8 CIV, and

274 deaths during 2012-2013 and 2013-2014, when influenza viruses and vaccines were similar.

275 properties in predicting the antigenicity of influenza viruses by a random forest model.

276 bility after only one passage indicates that influenza viruses can continue to evolve in galliform sp

277 ernal influenza immunisation in Nepal, where influenza viruses circulate throughout the year.

278 nza (HPAI) viruses along with other emerging influenza viruses continue to pose pandemic threats.

279 r, sequential infection of ferrets with H1N1 influenza viruses elicited an Igkappa-biased Ab response

280 cessfully to induce broad protection against influenza viruses in humans, and our limited data indica

281 replication and pathogenicity of these H5N1 influenza viruses in mice.

282 ted how preexisting antibodies to historical influenza viruses influenced HAI-specific antibodies and

283 y of the epidemiology and virology of animal influenza viruses is key to understanding pandemic risk

284 Most tests detected only influenza viruses or RSV.

285 on to seasonal infections, emerging pandemic influenza viruses present a continued threat to global p

286 H2 influenza viruses represent a pandemic threat due to con

287 Influenza viruses steadily evolve to escape detection by

288 spread of these mutations in circulating H1 influenza viruses that the previously subdominant, conse

289 tly available antibody-based LFA systems for influenza viruses, which offer discrimination between in

290 herapeutic protection against human or avian influenza viruses.

291 ated membrane scission during the budding of influenza viruses.

292 cacy and provide protection against emerging influenza viruses.

293 patient households and surrounding areas for influenza viruses.

294 ignificant human pathogens such as Ebola and influenza viruses.

295 compared to influenza VLPs without CCL28 or influenza VLPs physically mixed with sCCL28 (soluble) in

296 re than 8-month post-vaccination compared to influenza VLPs without CCL28 or influenza VLPs physicall

297 lar histones in that pulmonary injury during influenza was exacerbated.

298 Influenza was significantly associated with excess hospi

299 of influenza viral shedding in patients with influenza who have very few or no symptoms reflects thei

300 Kingdom to inform vaccination strategies for influenza, with extensions to make it easily adaptable t